A prespecified analysis of the SELECT trial, investigating semaglutide and its impact on cardiovascular outcomes, was published on 2025-01-01. This analysis specifically examined the relationship between semaglutide and cardiovascular outcomes in patients with overweight or obesity, considering both baseline and changes in adiposity measurements.
Background
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, widely recognized for its efficacy in managing type 2 diabetes and promoting weight loss. The broader SELECT trial, titled “Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity,” aimed to evaluate the cardiovascular safety and efficacy of semaglutide in individuals with established cardiovascular disease and overweight or obesity, but without diabetes. This prespecified analysis delves deeper into the mechanisms and modifying factors behind semaglutide's observed cardiovascular benefits.
Trial design
This publication reports a prespecified analysis derived from the comprehensive SELECT trial. The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) was designed to assess the long-term effects of semaglutide on major adverse cardiovascular events. This particular analysis focused on understanding how baseline adiposity measurements and subsequent changes in adiposity during treatment with semaglutide might influence or correlate with the observed cardiovascular outcomes.
Key results
The prespecified analysis explored the intricate relationship between semaglutide treatment, changes in adiposity measurements, and cardiovascular outcomes in the study population. The provided source information indicates that the analysis investigated these associations but does not include specific quantitative results such as hazard ratios, confidence intervals, or p-values from the findings.
What this means
The publication of this prespecified analysis from the SELECT trial offers valuable insights into the potential mechanisms underlying semaglutide's cardiovascular benefits. By examining the role of baseline adiposity and changes in adiposity, researchers and clinicians can gain a deeper understanding of how these factors may modulate treatment response. This type of analysis helps to elucidate whether the cardiovascular protective effects of semaglutide are solely mediated through weight reduction or if other adiposity-independent pathways are also at play. Such detailed investigations are crucial for optimizing patient selection and refining treatment strategies for individuals with overweight or obesity and cardiovascular risk.
Source
The information regarding this prespecified analysis of the SELECT trial was obtained from a publication indexed on PubMed on 2025-01-01. The article, titled “Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial,” is available via pubmed.ncbi.nlm.nih.gov.